Compare Dollar General Corp. (DG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs TransMedics Group Inc — how do they compare? Dollar General Corp. trades at $119.54 (market cap $26.49B), while TransMedics Group Inc trades at $87.76 (market cap $3.10B). The key difference: Dollar General Corp. is far larger — about 8.5× TransMedics Group Inc's market cap, and Dollar General Corp. pays a 1.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DG | TMDX | |
|---|---|---|
Market Cap | $26.49B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $156.26 | $150.42 |
52-Week Low | $95.94 | $61.99 |
Enterprise Value | $40.93B | $3.49B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.39, down 3.32% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.00 surpassing the $1.89 expectation. Positive cash flow trends and a declining debt-to-asset ratio (20.03 in 2025) support financial health. A dividend of $0.59 is scheduled for payment on July 21, 2026.
The outlook is cautiously optimistic, with a consensus price target of $128.45 offering ~5% upside. Analyst sentiment is bullish (52% Buy ratings), but risks include competitive pressure from Walmart and Amazon, margin compression from rising costs, and market saturation. Revenue growth is projected to reach $43.1B in 2026, though net margin remains thin at 3.63%.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
